Is Clexane (enoxaparin) required after a cesarean delivery, and how long should it be given?

VTE Prophylaxis After Cesarean Delivery

All women undergoing cesarean delivery require sequential compression devices (SCDs) starting before surgery and continuing until fully ambulatory, but pharmacologic prophylaxis with enoxaparin is only necessary when specific risk factors are present. 1, 2

Universal Mechanical Prophylaxis (All Cesarean Deliveries)

• Apply pneumatic sequential compression devices before skin incision and maintain continuously until the patient achieves complete ambulation (GRADE 1C). 1, 2
• SCDs are superior to elastic stockings and represent the minimum standard of care for all cesarean deliveries. 2

When Pharmacologic Prophylaxis (Clexane) IS Required

Major Risk Factors (Any ONE Warrants Enoxaparin)

• Prior personal history of deep vein thrombosis or pulmonary embolism. 1, 2
• Inherited thrombophilia (antithrombin deficiency, homozygous Factor V Leiden, homozygous prothrombin G20210A, compound heterozygosity). 1, 2
• Antiphospholipid antibody syndrome. 2

Minor Risk Factors (TWO OR MORE Warrant Enoxaparin)

• Advanced maternal age (≥35 years). 2
• Obesity (BMI ≥30 kg/m²). 2
• Current smoking. 2
• Family history of VTE in first-degree relative. 2
• Emergency cesarean section. 2
• Preeclampsia. 2
• Prolonged labor or postpartum hemorrhage >1 liter. 2

The threshold for pharmacologic prophylaxis is met when the absolute VTE risk exceeds 3%, which occurs with one major factor OR two or more minor factors. 2

Enoxaparin Dosing Regimens

Standard-Risk Patients (BMI <40 kg/m²)

• Enoxaparin 40 mg subcutaneously once daily. 1, 2, 3
• Initiate ≥4 hours after epidural catheter removal AND ≥12 hours after neuraxial block placement. 2, 3

Class III Obesity (BMI ≥40 kg/m²)

• Enoxaparin 40 mg subcutaneously every 12 hours (intermediate dosing, GRADE 2C). 1, 2
• Alternative: 0.5 mg/kg subcutaneously every 12 hours (weight-based approach). 2, 4
• Initiate ≥4 hours after epidural catheter removal AND ≥24 hours after neuraxial block placement (note the longer 24-hour requirement for intermediate dosing). 2, 3
• Standard 40 mg once-daily dosing is inadequate in Class III obesity and results in subtherapeutic anti-Xa levels in the majority of patients. 2, 4

Renal Impairment (Creatinine Clearance <30 mL/min)

• Switch to unfractionated heparin 5,000 units subcutaneously every 8–12 hours instead of enoxaparin. 1, 2
• UFH can be initiated as early as 1 hour after epidural catheter removal. 2

Duration of Prophylaxis

Standard-Risk Patients

• Mechanical prophylaxis: Until fully ambulatory (typically 24–48 hours postoperatively). 1, 2
• Pharmacologic prophylaxis: Minimum 7–10 days or until hospital discharge, whichever is longer. 2

High-Risk Patients (Prior VTE, Thrombophilia, or Multiple Persistent Risk Factors)

• Extended pharmacologic prophylaxis for 6 weeks postpartum (GRADE 2C). 1, 2
• Continue mechanical prophylaxis until ambulatory, then transition to enoxaparin alone for the full 6-week duration. 1, 2

When Enoxaparin Is NOT Necessary

Women undergoing cesarean delivery with NO identified risk factors require only early mobilization and mechanical prophylaxis (SCDs until ambulatory). 2

• In low-risk patients, the number needed to harm from pharmacologic prophylaxis (wound complications, hematoma) may exceed the number needed to treat for VTE prevention. 2
• Routine pharmacologic prophylaxis in all cesarean patients increases bleeding risk without meaningful VTE reduction. 2

Common Pitfalls to Avoid

• Do not use standard 40 mg once-daily dosing in Class III obesity—this is the most common dosing error and leaves patients inadequately protected. 2
• Do not initiate intermediate-dose enoxaparin (40 mg every 12 hours) before 24 hours post-neuraxial block—this increases spinal hematoma risk. 2
• Do not use direct oral anticoagulants (DOACs) postpartum—insufficient safety data exists for apixaban, rivaroxaban, or dabigatran in this population. 2
• Do not delay enoxaparin beyond 12 hours post-neuraxial block in standard-risk patients or beyond 24 hours in obese patients requiring intermediate dosing. 2

Evidence Quality Considerations

The 2020 SMFM/ACOG guideline provides the foundational framework (GRADE 1C for universal mechanical prophylaxis, GRADE 2C for pharmacologic decisions), while the 2026 Praxis synthesis incorporates updated ACCP risk stratification showing that two minor factors meet the 3% VTE threshold warranting pharmacologic intervention. 1, 2 The weight-based dosing recommendation for Class III obesity is supported by a 2015 prospective cohort demonstrating that 86% of morbidly obese women achieved adequate anti-Xa levels with 0.5 mg/kg dosing versus only 26% with fixed BMI-stratified dosing. 4